Presentation Time: 10:30 a.m. (Pacific) Monday, January 12, 2004
DENVER, Dec. 23 /PRNewswire-FirstCall/ -- Myogen, Inc. (Nasdaq: MYOG), a
biopharmaceutical company focused on the discovery, development and
commercialization of small molecule therapeutics for the treatment of
cardiovascular disease, today announced that J. William Freytag, President and
CEO, will present a corporate overview at the 22nd Annual JPMorgan Healthcare
Conference.
The presentation will take place at 10:30 a.m. (Pacific) on Monday,
January 12, 2004 in the Westin St. Francis Hotel, 335 Powell Street, San
Francisco, California. There will be a live webcast of the presentation from
the conference. The webcast will be accessible through a link posted on the
investor relations section of the Myogen website at
http://investor.myogen.com/. The webcast will be available for replay on
Myogen's website until January 28, 2004.
Myogen is a biopharmaceutical company focused on the discovery,
development and commercialization of small molecule therapeutics for the
treatment of cardiovascular disorders. Myogen currently markets one product
in Europe for the treatment of acute decompensated heart failure and is
developing three product candidates for three distinct cardiovascular
indications. The Company also conducts a target and drug discovery research
program focused on the development of disease-modifying drugs for the
treatment of chronic heart failure and related cardiovascular disorders.
Please visit our website at http://www.myogen.com.
Safe Harbor Statement
This press release and the anticipated presentation contain
forward-looking statements that involve significant risks and uncertainties,
including those discussed in this release, those to be discussed in the
presentation and others that can be found in the "Risk Factors" section of
Myogen's Prospectus filed on October 30, 2003 and in our Form 10-Q filed on
December 4, 2003. Myogen does not undertake any obligation to update any
forward-looking statements contained in this document or the anticipated
presentation as a result of new information, future events or otherwise. The
Company cautions investors not to place undue reliance on the forward-looking
statements contained in this press release or the presentation. No
forward-looking statement can be guaranteed and actual events and results may
differ materially from those projected.
SOURCE Myogen, Inc.
 back to top
Related links:
http://investor.myogen.com
http://www.myogen.com
CONTACT:
Derek K. Cole, Director, Investor Relations
of Myogen, +1-303-464-3986, derek.cole@myogen.com
|
